A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Dosing is based on the person’s weight and the treatment at list price would cost around £510,000 per year for an adult ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer spokesperson told Pharmaceutical Technology in ...

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. It is almost exclusively found ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Novo Nordisk’s haemophilia A candidate has met the primary endpoints in a Phase III trial. Image credit: Shutterstock / JHVEPhoto Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely ...

Former pupils of a school where disabled children were infected with contaminated blood are seeking damages from its trust at ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

Haemophilia A is a rare disorder that means sufferers do not have enough of the clotting factor VIII in their blood or it does not work properly. This means they cannot form strong clots and bleed ...